Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Raises $32M from Stock Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clinical Data today announced it has closed on its previously announced offering, raising $32 million.

Net proceeds from the sale, after underwriting discounts and commissions and estimated offering expenses, are expected to be about $30 million.

BMO Capital Markets was the sole book running manager. Wedbush PacGrow Life Sciences and Roth Capital Partners acted as co-managers in the offering.

The Newton, Mass.-based firm will use the proceeds to develop and commercialize its lead therapeutic, vilazodone, for treatment of depression. Proceeds will also be used to fund clinical trials for its coronary vasodilator, Stedivaze, currently in Phase III development; for the continued development of other products and drug candidates; and for working capital and general corporate purposes.

Clinical Data announced last week its plans to offer the stock. At the time, it said it expected to raise $27.8 million through the sale of 1,945,576 shares at $14.30 per share. Today, the company said that it also sold 291,836 shares pursuant to the full exercise of an over-allotment granted to the underwriters, for a total of 2,237,412 shares sold at $14.30 per share.

The shares offered by the company exhausted all remaining shares on its existing shelf registration statement, it said.

Clinical Data raised net proceeds of about $44.1 million in a public offering of 2.75 million shares of common stock last October.

Shares of the company's stock were down 3.7 percent at $15.22 in mid-afternoon trade Monday.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.